Phase II trial of gemcitabine in advanced non-small-cell lung cancer

Wiener Klinische Wochenschrift

Volumn 109, Issue 17, 1997, Pages 688-691

  Malayeri, Reza ^a   Ulsperger, Ernst ^b   Baumgartner, Gerhard ^b   Forstner, Bernhard ^c   Aigner, Kurt ^c   Hubner, Marianne ^d   Kummer, Friedrich ^d   Krajnik, Gerhard ^a   Zöchbauer, Sabine ^a   Krejcy, Kurt ^e   Huber, Heinz ^a   Pirker, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Research Division   (Austria)

^c ELISABETHINEN HOSPITAL   (Austria)

^d Medizinische Abteilung   (Austria)

^e Eli Lilly and Company   (Austria)

Author keywords

gemcitabine; non small cell lung cancer; palliation of symptoms; phase II trial

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; SYMPTOM; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AUSTRIA; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 9844250753     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Souquet PJ, Chauvin F. Boissel JP. Cellarino R. Cormier Y, Ganz PA, et al (1993) Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342: 19-21
2. Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer how much benefit is enough? J Clin Oncol 11: 1866-1872
3. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909
4. Zöchbauer S, Krajnik G, Huber H (1994) Bronchuskarzinom. Entstehung, Diagnose, Therapie, Prognose. Wien Klin Wochenschr 106: 431-447
5. Lilenbaum RC, Green MR (1993) Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 11: 1391-1402
6. Kaye SB (1994) Gemcitabine: current status of phase I and II trials. J Clin Oncol 12: 1527-1531
7. Abratt RP, Bezwada WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540
8. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498
9. Poplin EA, Corbett T. Flaherty L. Tarasoff PG, Redman BG. Valdivieso M, et al (1992) Difluorodeoxycytidine (dFdC)-gemcitabine: a phase I study. Invest New Drugs 10: 165-170
10. O'Rourke TJ, Brown TD, Havlin K. Kuhn JG, Craig JB, Bums HA, et al (1994) Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 30: 417-418
11. Miller AB, Hoogstraten B, Staquet M. Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
12. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single agent activity of weekly gemcitabine in advanced non-small-lung cancer: a phase II study. J Clin Oncol 12: 1821-1826
13. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier R, Groen HJM, et al (1996) Activity of gemcitabine in patients with non-small-cell lung cancer: A multi-centre, extended phase II study. Eur J Cancer 32A: 243-248
14. Manegold Ch, von Pawel J, Conte PF. Dornhoff W, van Walree NC. ten Bokkel Huinink WW. et al (1996) Randomised phase 2 study of gemcitabine (GEM) versus cisplatin/etoposide (C/E) m patients with advanced non-small cell lung cancer (NSCLC). Annals Oncol 7 [Suppl] 5: 3
15. Krajnik G, Mohn-Staudner A, Marhold F, Malayeri R, Zöchbauer S. Kummer F, et al for the Austrian Association for the Study of Lung Cancer (1997) Vinorelbine/gemcitabine in advanced non-small-cell lung cancer (NSCLC): a phase I trial. Proc ASCO 16: 206 abstract 722
16. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15: 744-749
17. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F. et al (1997) Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15: 297-303
18. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367
19. Pirker R, Krajnik G, Zöchbauer S, Malayeri R, Kneussl M, Huber H (1995) Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Annals Oncol 6: 833-835
20. Breille J, Le Chevalier T, Zalcberg JR, Millward MJ, Monnier A, Douillard JY, et al (1996) Overview on taxo-tere-cisplatin (TXT-CDDP) combination in non-small-celi lung cancer (NSCLC). Annals Oncol 7 [Suppl] 5. 90
21. Pirker R, Zöchbauer S, Krajnik G, Salzer GM, Eckersberger F, Huber H (1996) Adjuvant and induction therapies in non-small-cell lung cancer. Onkologie 19: 221-225